Patritumab Deruxtecan BLA Submission Receives Complete …
WEBJun 26, 2024 · Patritumab deruxtecan was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration in December 2021 for the treatment of patients with EGFR-mutated locally advanced or metastatic NSCLC with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.
Patritumab Deruxtecan Demonstrated Statistically Significant ...
WEBSep 17, 2024 · The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement versus platinum plus pemetrexed induction ...
Patritumab Deruxtecan Demonstrated Statistically Significant
WEBSep 17, 2024 · Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada.
Patritumab Deruxtecan Granted Priority Review in the U.S. for
WEBDec 22, 2023 · Patritumab deruxtecan was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration in December 2021 for the treatment of patients with EGFR-mutated locally advanced or metastatic NSCLC with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.
WEBJun 26, 2024 · Patritumab deruxtecan was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration in December 2021 for the treatment of patients with EGFR-mutated locally advanced or metastatic NSCLC with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.
WEBSep 10, 2023 · 2 trial showed that patritumab deruxtecan (HER3-DXd) demonstrated clinically meaningful and durable responses in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following disease progression with an EGFR TKI and platinum-based chemotherapy.
Patritumab Deruxtecan Active in HER3-Expressing ... - ASCO Daily News
WEBJun 4, 2022 · The HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan is active in patients with heavily pretreated HER3-expressing metastatic breast cancer, according to results of a phase 1/2 study.
FDA Grants Breakthrough Therapy Status to Patritumab Deruxtecan …
WEBJan 4, 2022 · Patritumab deruxtecan (U3-1402), a potential first-in-class HER3 directed antibody-drug conjugate, was granted breakthrough therapy designation by the FDA for the treatment of patients with metastatic or locally advanced, EGFR -mutant non–small cell lung cancer (NSCLC), according to a press release from developer Daiichi-Sankyo. 1.
Patritumab Deruxtecan Produces Durable Responses in Patients …
WEBJun 7, 2021 · Results from U31402-A-U102, a phase I dose escalation and dose expansion study, show that patritumab deruxtecan has durable efficacy in patients with non-small cell lung cancer, regardless of EGFR tyrosine kinase inhibitor resistance mechanisms.
Daiichi Sankyo and MSD’s ADC improves progression-free survival …
WEB6 days ago · Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with ...
- Some results have been removed